Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Spinal CSF leaks are considered as rare disease. They cause a variety of symptoms, mainly culminating in a chronic headache syndrome. Crucially, yet often disregarded, the disease holds the potential for cure. The multitude of symptoms, and their inconsistency over time are just two of many challenges preventing timely diagnosis and treatment in many patients.
Spinal CSF leaks can occur after intentional or accidental dural puncture (post-dural puncture headache - PDPH) or spontaneously (spontaneous intracranial hypotension - SIH). Awareness is steadily increasing with simultaneous increase of recognized patients. Yet, research and diagnostic is mainly provided by few specialized centers, as e.g. Freiburg. Thus, many observations point towards a large non-diagnosed and non-recognized number of patients, most likely being misdiagnosed and mistreated.
Objective: The aim of the registry is to collect structured information on the frequency, cause, symptoms, diagnostic procedures, treatment options and long-term outcome. With the help of the registry, we would like to contribute to a better understanding and treatment of the diseases.
Methods: Prospective, longitudinal registry on patients with suspected SIH or PDPH, including data on demographics, clinical presentation, diagnostic findings, treatment, at treatment outcome.
Spinal CSF leaks have a severe impact on quality of life and health. Symptoms vary from chronic headache syndrome to intracranial bleeding, cognitive decline, and coma. Crucially, yet often disregarded, the disease holds the potential for cure.
Lumbar dural leaks can arise from commonly performed medical interventions such as diagnostic lumbar punctures, spinal anesthesia, spinal infiltrations, or incidental dural punctures during epidural analgesia in obstetric care, resulting in post-dural puncture headache (PDPH).
Additionally, a notable fraction of spinal CSF leaks manifests as spontaneous intracranial hypotension (SIH), which derives from different types of spontaneous leaks along the Spine and remains broadly under-recognized.
The main clinical symptoms of spinal CSF leaks are orthostatic headaches with a most often defined beginning, typically accompanied by hearing impairment and dizziness, worsened by exercise and movement. Additionally, other manifestations are known, such as cognitive decline, bilateral brachial amyotrophy, paradox headache, fatigue, and many more. In patients presenting with spinal CSF leaks, the accurate diagnosis often eludes clinicians, leading to frequent misdiagnoses of chronic migraine, fatigue, or psychiatric conditions. Many patients endure months, if not years, before a diagnosis of a treatable condition is finally established. The heterogeneity of the symptoms can appear inconsistent or even paradoxical, posing diagnostic challenges. The extent of possible long-term deterioration is not recognized.
The reported incidence of PDPH fluctuates considerably, ranging from 2 to 40 per 100 procedures performed. This variance is influenced by patient-related factors (e.g., age, gender, pregnancy status) and procedural factors (e.g., needle size and type). PDPH, according to current criteria, occurs within 5 days after a dural puncture. Nevertheless, there are widely underestimated pitfalls: a dural puncture is not always recognized by the person performing an epidural procedure, symptoms can occur after more than 5 days, and disease courses can be chronic. These facts are widely unknown, leading to largely hidden figures of patients being under or misdiagnosed and, thus, not treated. Moreover, PDPH is primarily observed following unintentional dural puncture during the administration of obstetric anaesthesia and analgesia to parturients.
Spontaneous intracranial hypotension (SIH) can be caused by ventral, lateral, or sacral spinal leaks or by CSF-venous fistulae, which was first described in 2014. An annual incidence rate of ~ 4/100,000 was estimated in 2022. This rate is likely underestimated as it only includes confirmed cases, thus recognized cases within a widely non-recognized entity. Often, patients are neither identified nor directed to the appropriate MRI, which, in numerous instances, could lead to the correct diagnosis. Even when SIH is identified, non-targeted epidural blood patches in the lumbar region are often not administered due to perceived elevated risks. An epidural blood patch might be able to help to heal the leak. At the same time, it must be noted that even long-term improvement does not necessarily indicate closure of the leak and prevention of long-term sequelae, such as superficial siderosis. Invasive diagnostics are not employed to pinpoint the location, and treatment to seal the leak is not consistently pursued. The effects of treatment are often immediate and can be successful even in chronic patients. Evidence shows that leaks are held open by new membranes (Neo-membranes) that prevent spontaneous healing. Thus, the correct localization of such a leak and targeted sealing or close follow-ups should be initiated.
The management approaches for SIH and PDPH significantly deviate from standard pain management strategies employed for other types of headaches. Noteworthy interventions include the application of blood patches and even surgical measures to seal the leak, offering curative solutions. Those enduring chronic spinal CSF leaks experience profound limitations in their health-related quality of life, comparable to those with chronic immunological diseases or cancer. Overlooking the diagnosis and management of spinal CSF leaks may precipitate progressive deterioration, with the potential for persistent sequelae like superficial siderosis, syndromes mimicking frontotemporal dementia (FTD), and chronic subdural hematoma formation.
This registry aims to set ground for standardized, prospective demographic, diagnostic and treatment data assessments, and patient self-reported outcome measures.
Collecting this data is essential to potentially exploring risk factors, understanding outcome predictors, and refining diagnostics. Additionally, standardized data collection will allow the appropriate designing of urgently needed randomized trials.
Aims:
Primary aim:
To describe the proportion of patients diagnosed with SIH or PDPH
Secondary aims:
Method:
The registry is prospective, longitudinal and currently monocentric*. Diagnostic, treatment, and follow-up procedures follow clinical standard operating procedures (SOP) according to the suspected diagnosis and the clinical findings.
Routinely assessed data of the initial diagnostic workup and the individual's disease course with or without treatment will be collected over 2 years per individual. The investigators' semi-annual meetings ensure the achievement of the register's predefined aims.
There are no specific risks or benefits for the patients participating in this registry. Any procedure will be performed according to clinical standards as indicated. There will be no additional visits to the hospital or the ambulatory. There will be no additional imaging performed, especially no additional radiation.
A merely intrinsic benefit might exist for the patient supporting this study and supporting medical research.
As this is an explorative and observational study on rare diseases without formal sample size estimation, we limit the study by time of duration (10 years).
Patients suffering from rare diseases most often face delays in diagnostics and treatments. To underscore this known burden: By an estimated population of 1.74 Mio in the Freiburg area and an incidence rate of SIH of about 5/100.0004, approximately 85 patients should be expected per year stemming from this area. Freiburg is the only center offering adequate diagnostic pipelines for these patients. Despite the increasing awareness, the number of patients diagnosed in the area adjunct to the Freiburg CSF center is within a range of 15 to 20 patients per year, thus still too low compared to the expected number with many patients unrecognized, and or underdiagnosed.
Our current numbers of confirmed SIH treatments range from 100 per year with patients being referred throughout Germany and about 15-20 international patients per year. We expect this rate to rise within the next few years. The number of PDPH patients with a focus on persistent PDPH patients is currently rapidly increasing. We see about 40-60 per year.
Interim-Evaluation of the Registry's primary and secondary descriptive aims will be performed and reported as a step-wise, dynamic approach:
The secondary objectives, which involve comparisons, the exploration of diagnostic markers, and risk factors, will be addressed using a dynamic biostatistical model: The analysis will only be conducted after a power analysis deems the observed sample adequate.
Proportions will be presented as a percentage with 95% confidence interval (CI).
The sata of patients with different types of spinal CSF leaks will be summarized using descriptive statistics, i.e. median and quartiles for continuous and absolute and relative frequencies for categorical variables, regarding their clinical, laboratory, and diagnostic findings, and number of diagnostic and therapeutic procedures needed.
Furthermore, the proportion of SIH patients with different spinal CSF leak types
Age, sex, BMI, clinical presentation, and diagnostic findings between different spinal CSF leaks will be compared using the Mann-Whitney-Wilcoxon test and Chi2 test for continuous and categorical variables, respectively.
A multivariable logistic regression for the presence of SIH, PDPH, and chronic PDPH, respectively, will be constructed using the clinical and diagnostic parameters with some evidence for a difference according to the presence of a spinal CSF leak (p < 0.2). The potential nonlinearity of the age effect is evaluated based on a residual analysis of the regression model. Odds ratios with 95% CI will be reported. Using bootstrapping, we will present a ROC curve and AUC with 95% Due to the exploratory approach,, no correction for multiple testing will be performed.
A multivariable linear regression for imaging findings (especially Bern Score, presence of SLEC, vand olumetries), and for the patient-reported outcomes will be constructed using the clinical and diagnostic parameters at admission with some evidence for a difference (p<0.2). Adjusted R-squares, Beta-coefficients with 95% CI, standard errors will be reported.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| spinal CSF leak | Patients with suspected spinal CSF leak based on one of the following:
|
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Primary Diagnosis given after primary workup (yes/no) |
| up to 4 weeks after inclusion |
| Measure | Description | Time Frame |
|---|---|---|
| SIH/PDPH - Experience of the local team | Number of patient with suspicion for SIH work-up/year | at time of inclusion |
| SIH/PDPH - Patients' demographics | Country, City |
| Measure | Description | Time Frame |
|---|---|---|
| SIH/PDPH - Follow up-Reported adverse events related to treatment (yes/no) | Rebound hypertension, Reoccurrence of the leak, Suture insufficiency, Bleeding, Sensory deficits, Motor deficits, Gait ataxia, Bladder dysfunction, Bowl dysfunction, Others | 4 weeks and 3 month after treatment |
| SIH/PDPH - Follow up-Duration of treatment for rebound hypertension after therapy of the CSF leak |
Inclusion Criteria:
Patients with suspected spinal CSF leak based on one of the following
Informed consent
Exclusion Criteria:
a) Symptoms beeing conclusively explained by another known diagnosis
Not provided
Not provided
Not provided
Not provided
The registry is an explorative study on patients suffering from a rare disease - therefor it is aimed to include all eligible patients for a time-limit of 10 years. All patients with suspected spinal CSF leak will be approached and informed about the registry. In case of legal incapacity, the caregivers will be approached. The inclusion of this vulnerable group is considerable as they represent a small but very important subgroup of patients suffering from demntia stemming from a traetable cause.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Katharina Wolf, Dr. med. | Contact | +49 761 270-50010 | katharina.wolf@uniklinik-freiburg.de | |
| Florian Volz, Dr. med. | Contact | +49 761 270-50 | florian.volz@uniklinik-freiburg.de |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medical Center - University of Freiburg, Germany | Recruiting | Freiburg im Breisgau | 79106 | Germany |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34553617 | Background | Schievink WI, Maya MM, Moser FG, Simon P, Nuno M. Incidence of spontaneous intracranial hypotension in a community: Beverly Hills, California, 2006-2020. Cephalalgia. 2022 Apr;42(4-5):312-316. doi: 10.1177/03331024211048510. Epub 2021 Sep 23. | |
| 35338080 | Background | Lashkarivand A, Eide PK. Brain Sagging Dementia-Diagnosis, Treatment, and Outcome: A Review. Neurology. 2022 May 10;98(19):798-805. doi: 10.1212/WNL.0000000000200511. Epub 2022 Mar 25. |
| Label | URL |
|---|---|
| Spinal CSF Leak Foundation - Home - Spinal CSF Leak Foundation. Accessed September 5, 2023 | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002558 | Cerebrospinal Fluid Otorrhea |
| D051299 | Post-Dural Puncture Headache |
| D065634 | Cerebrospinal Fluid Leak |
| D035583 | Rare Diseases |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D006259 | Craniocerebral Trauma |
| D020196 | Trauma, Nervous System |
Not provided
Not provided
Not provided
Not provided
Not provided
| at time of inclusion |
| SIH - Previously received treatment at time of inclusion (yes/no) | Medical SIH treatment, Other symptomatic treatment, Untargeted lumbar blood patch, Targeted blood patch, Targeted fibrin patch, Endovascular embolization, Minimally invasive surgery, Open surgery - dorsal approach, Open surgery-ventral approach, Open surgery-transforaminal approach, Discectomy, Laminectomy, Stabilization procedures, Surgery, other techniques | at time of inclusion |
| SIH/PDPH - age | years | at time of inclusion |
| SIH/PDPH - sex | male female diverse | at time of inclusion |
| SIH/PDPH - height | height in meter (m) | at time of inclusion |
| SIH/PDPH - weight | kilogram (kg) | at time of inclusion |
| SIH/PDPH - modified Ranking scale | range in 0-6, 0 indicating best health | at time of inclusion |
| SIH/PDPH - pre-existing Neurological deficits (yes/no) | Neurological deficits due to previously attempted treatments at the time of inclusion | at time of inclusion |
| SIH/PDPH - Neurological deficits in routine clinical testing | descriptive | at time of inclusion |
| SIH - Montreal cognitive Assessment | range 0-30, 30 indicating best performance | at time of inclusion |
| SIH - Trail-making test part B | in minutes needed to fulfill the task | at time of inclusion |
| PDPH -BMI | kg/m^2 | at time of inclusion |
| SIH/PDPH - Regular use of stimuli > 6 months (yes/no) | Nicotine, Alcohol, Recreational drugs | at time of inclusion |
| SIH/PDPH - Headache-Impact-Test (HIT)-6 | Headache-Impact-Test (HIT)-6 range 36 to 78 points, 78 indicating highest impact of headaches. | at time of inclusion |
| SIH/PDPH - 5 dimensions /5 levels European Quality of life questionaire (EQ-5D-5L) Index | <0 to 1, with 1 indicating unimpaired health | at time of inclusion |
| SIH/PDPH - Self-Administered Comorbidity Questionaire (SCQ) | 13-item Self-Adminestered Comorbidity Questionaire (SCQ), range 0 to 39, 0 indicating lowest burden | at time of inclusion |
| PDPH - Patient'S Global Impression of Change (PIGC) | range 7 - 42, 7 indicating highest improvement | at time of inclusion |
| SIH - Opening pressure on lumbar puncture if performed (not recommended in routine), or myelogram | cmH2O | up to 4 weeks |
| SIH/PDPH - Total Bern-Score MRI head according to Dobrocky et al. | range 0 to 9 with 9 indicating highest likelihood of a spinal CSF leak | up to 4 weeks |
| SIH/PDPH - Subitems Bern-Score MRI head according to Dobrocky et al. | Meningeal enhancement (yes/no), Subdural fluid (yes/no), Venous Distention (yes/no), Effaced suprasellar distance (yes/no), Effaced mamillopontine distance (yes/no), Effaced prepontine distance (yes/no) | up to 4 weeks |
| SIH - MRI head - Superficial Siderosis | (yes/no) | up to 4 weeks |
| SIH - MRI head - Layered calvarial hyperostosis | (yes/no) | up to 4 weeks |
| SIH - Sinus vein thrombosis | (yes/no) | up to 4 weeks |
| SIH/PDPH - Volumetry of the CSF-space MRI head & spine | mm^3 | up to 4 weeks |
| SIH/PDPH - Volumetry of the CNS MRI head & spine | mm^3 | up to 4 weeks |
| SIH/PDPH - Imaging Density score | Density scores of the intracranial compartments MRI head & spine | up to 4 weeks |
| SIH/PDPH - Total radiation dose applied per diagnostic procedure with radiation performed | Sievert | at primary workup |
| SIH - Myelography number | Number of myelographies performed for precise localization | up to 24 weeks |
| SIH - Type of myelography technique applied (yes/no) | conventional,digital subtraction, dynamic CT, Cone-beam CT, Photon-counting CT, fluoroscopy, Other (specify) | up to 4 weeks |
| SIH - Adverse events during myelography (yes/no) | nausea, dizziness/vertigo, emesis, allergic reaction, seizure, treatment intensive care unit (independent of cause)) | up to 4 weeks |
| SIH - Headache before and after myelogram | in 0-10, 10 numeric rating scale | up to 4 weeks |
| SIH - Positioning during index myelography that proofs the leak (yes/no) | prone, lateral decubitus, supine | up to 4 weeks |
| SIH - myelography that proofs the leak performed applying (yes/no) | resisted insipration, pressuization, valsalva maneuver | up to 4 weeks |
| SIH/PDPH - Lumbar Infusiontest - Pressure at baseline | pressure (mmHg) | up to 4 weeks |
| SIH/PDPH - Lumbar Infusiontest - Resistence to CSF outflow (Rcsf) | mmHg/(ml/min) | up to 4 Weeks |
| SIH/PDPH - Lumbar Infusiontest - Elastance | Elastance coefficient (1/ml) | up to 4 weeks |
| SIH/PDPH - Lumbar Infusiontest - Pressure-Volume-Index | ml | up to 4 weeks |
| SIH/PDPH - Lumbar Infusiontest - Needle resistance | up to 4 weeks |
| SIH/PDPH - PET-CT - Evidence of CSF-loss (yes/no) | up to 4 weeks |
| SIH/PDPH - PET-CT if performed - | half-life of the tracer in the CSF space (minutes) | up tp 4 weeks |
| SIH/PDPH - Laboratory parameters at diagnosis (normal/abnormal) |
| up to 4 weeks after inclusion |
| SIH - CSF leak types identified by dynamic myelography (yes/no) |
| up to 4 weeks |
| SIH - Multiples leaks (yes/no) | up to 4 weeks |
| SIH - Level of spinal CSF leak (spinal segment) and side in myelogram | up to 4 weeks |
| SIH - In case of surgery: spinal segment and side confirmed? (yes/no) | up to 4 weeks |
| SIH/PDPH - Experience of leading interventionalist in SIH-diagnostics/year | up to 4 weeks |
| SIH/PDPH - Disease duration at time of therapy | month | up to 4 weeks |
| SIH/PDPH - Therapy performed after CSF leak diagnosis (yes/no) | Untargeted lumbar blood patch, Targeted blood patch, Targeted fibrin patch, Endovascular embolization, Minimally invasive surgery with patching, Minimally invasive surgery with clipping, Minimally invasive surgery with disconnection, Open surgery, dorsal approach, Open surgery, ventral approach, Open surgery, transforaminal approach, Surgery, other techniques, Medical PDPH treatment, Other symptomatic treatment, e.g. infiltration N. occipitalis, Untargeted lumbar platelet-rich fibrin patch | up to 4 weeks |
| SIH/PDPH - Experience of leading surgeon in SIH/PDPH-surgeries/year | in numbers of SIH/PDPH-surgeries/year | up to 4 weeks or longer, depending on the number of surgeries |
| SIH/PDPH - Interventions needed addressing secondary complications of spinal CSF leaks, especially chronic subdural hematoma | Twist drill craniostomy (yes/no), Burr hole craniostomy (yes/no ), Mini craniotomy (yes/no), Conventional trepanation (yes/no), Use of drains and any form of controlled lavage (saline and or clot lysis) (yes/no,), Embolization of MMA (middle meningeal arteria) (yes/no), Other intervention (yes/no) | up to 4 weeks |
| PDPH - Event of putative dural puncture | date | up to 4 weeks |
| PDPH - Event of putative dural puncture (yes/ no) |
| up to 4 weeks |
| SIH/PDPH - adverse events related to current treatment at discharge (yes/no) | Rebound hypertension, Persistence/Reoccurrence of the leak, Suture insufficiency, Infect (systemic/local), Bleeding, Sensory deficits, Motor deficits, Gait ataxia, Bladder dysfunction, Bowl dysfunction, Others | up to 4 weeks |
| PDPH - Lumbar segment of putative dural puncture known (yes/no) | up to 4 weeks |
| PDPH - Puncture under imaging guidance | "location truly known" | up to 4 weeks |
| PDPH - Duration between (putative) dural puncture until the onset of symptoms | days | up to 4 weeks |
| PDPH - Time to first blood patch | days | up to 4 weeks |
| PDPH - Number of bloodpatches received before admission | up to 4 weeks |
| PDPH - Prior treatments at the time of admission (yes/no) | Fluids, Caffeine, Bedrest, Medical treatment, Other treatment, e.g., infiltrations, Untargeted lumbar bloodpatch, Surgery | up to 4 weeks |
| PDPH - Post-dural puncture pseudomeningocele ("arachnoid bleb") | (yes/no) | up to 4 weeks |
| PDPH - Spinal Segment location of the "arachnoid bleb" | up to 4 weeks |
| PDPH - Identified CSF leak types by dynamics myelography and/or intraoperatively: | ventral post-dural puncture leak, dorsal post-dural puncture pseudomeningocele ("arachnoid bleb"), dorsal post-dural puncture leak None | up to 4 weeks |
| PDPH - Intraoperatively Identified membranes (yes/no) | neo-membranes (pseudo dura), webs, funnels | up to 4 weeks |
| PDPH - Dinosaur-tail sign (yes/no) | at time of inclusion |
| PDPH - specific segment of identified intraoperative membranes (descriptive) | up to 4 weeks |
| PDPH - CSF leak types identified by dynamic myelography and/or intraoperatively | ventral post-dural puncture leak, dorsal post-dural puncture pseudomeningocele ("arachnoid bleb"), dorsal post-dural puncture leak, None | up to 4 weeks |
| PDPH - Diagnostic procedures performed (yes/no, number) | CT Head, MRI head, MRI spine, Dynamic digital subtraction myelogram, Dynamic CT-myelogram, Photon-counting CT-myelogram, Cone-beam myelogram, Infusion testing, PET-CT, Other (to exclude/confirm alternative diagnosis) | uo to 4 weeks |
| PDPH - Volume lumbar bloodpatch | ml | up to 4 weeks |
| SIH/PDPH - work capacity | range 0 to 5, 0 indicating full capacity | at time of inclusion |
| SIH/PDPH -complaints |
| at time of inclusion |
| SIH/PDPH - headache severity | range 0 to 10, 10 indicating most severe pain | at time of inclusion |
| SIH/PDPH - Days within the last month |
| at time of inclusion |
| SIH/PDPH - maximum duration being continuously upright | hours | at time of inclusion |
| SIH/PDPH - severeness of dizziness | - in 0 to 10, 10 being most severe | at time of inclusion |
| SIH/PDPH - Severeness of shoulder- and neck pain | - in 0 to 10, 10 being most severe | at time of inclusion |
| SIH/PDPH - severeness of nausea | - in 0 to 10, 10 being most severe | at time of inclusion |
| SIH/PDPH - severeness of hearing disturbances and tinnitus | - in 0 to 10, 10 being most severe | at time of inclusion |
| SIH/PDPH - severeness of cognitive deficits | - in 0 to 10, 10 being most severe | at time of inclusion |
| SIH/PDPH - severeness of visual disturbances | - in 0 to 10, 10 being most severe | at time of inclusion |
| SIH/PDPH - . ability to focus and concentrate | rated between 0 to 5, with 5 indicating highest burden | at time of inclusion |
| SIH/PDPH - MRI spine: Spinal longitudinal extradural fluid collection (SLEC) (yes/no) | up to 4 weeks |
| SIH/PDPH - MRI-spine: DiverTICula (TIC) ≥8mm (yes/no) | number of TICs ≥8mm | up to 4 weeks |
| SIH/PDPH - Volumetry of epidural spinal veins at C2 | mm^3 | up to 4 weeks |
| SIH/PDPH - MRI spine: Enlarged cervical epidural spinal veins at C2 | yes/no | up to 4 weeks |
| SIH/PDPH - lumbar infusion test - pressure at tilt down | mmHg | up to 4 weeks after inclusion |
| SIH/PDPH - lumbar infusion test - pressure at tilt up 10° | mmHg | up to 4 weeks after inclusion |
| SIH/PDPH - lumbar infusion test - pressure at tilt up 30° | mmHg | up to 4 weeks after inclusion |
| SIH/PDPH - lumbar infusion test - pressure at plateau | mmHg | up to 4 weeks after inclusion |
| SIH/PDPH - Laboratory parameters at diagnosis (decriptive) |
| up to 4 weeks after inclusion |
| SIH/PDPH - Lumbar Infusiontest - amplitude at baseline | mmHg | up to 4 weeks |
| SIH/PDPH - lumbar infusion test - amplitude at tilt down | mmHg | up to 4 weeks after inclusion |
| SIH/PDPH - lumbar infusion test -amplitude at tilt up 10° | mmHg | up to 4 weeks after inclusion |
| SIH/PDPH - lumbar infusion test - amplitude at tilt up 30° | mmHg | up to 4 weeks after inclusion |
| SIH/PDPH - lumbar infusion test - amplitude at plateau | mmHg | up to 4 weeks after inclusion |
| SIH/PDPH - PET-CT if performed - | half-life of the tracer o0ver the convexities (minutes) | up tp 4 weeks |
| SIH/PDPH - Results of neuropathological tissue analysis if assessed (descriptive) | epidural membranes (descriptive) arachnoid funnels (descriptive) diverticula (descriptive) epidural vessels (descriptive) | up to 6 weeks |
| SIH/PDPH - phase-contrast MRI : CSF-velocity | cm/s | up to 4 weeks |
| SIH/PDPH - phase-contrast MRI: Stroke-volume CSF | ml | up to 4 weeks |
| SIH/PDPH - phase-contrast MRI: Spinal cord motion | mm | up to 4 weeks |
| SIH/PDPH - phase-contrast MRI: Spinal cord velocities | cm/s | up to 4 weeks |
| SIH/PDPH - MRI spine: Bud-on-branching sign (yes/no) | up to 4 weeks |
| SIH/PDPH - MRI spine: Localized flow-voids in sagittal spine T2 images (yes/no) | up to 4 weeks |
days |
| 4 weeks after treatment |
| SIH/PDPH - Follow up-Average dosage of acetazolamide per day | mean mg/d | 4 weeks after treatment |
| SIH/PDPH - Follow up - Total Bern-Score, according to Dobrocky et al. | range 0 to 9, 9 indicating highest likelihood of spinal CSF leak | 3 months after treatment |
| SIH/PDPH - Follow up - Subitems Bern-Score, according to Dobrocky et al. |
| 3 months after treatment |
| SIH/PDPH - Follow up - Spinal longitudinal extradural fluid collection at site of the leak (SLEC) (only if present before) | yes /no | 3 months after treatment |
| SIH/PDPH - Follow up - Headache-Impact-Test (HIT)-6 | range 36 to 78 points, 78 indicating highest impact of headaches | 3, 6, 12 & 24 months after treatment |
| SIH/PDPH - Follow up - 5 dimension/ 5 levels European Quality of life questionnaire (EQ-5D-5L) | <0 to1, 1indicating unimpaired health | 3, 6, 12, & 24 months after treatment |
| SIH/PDPH - Follow up - Patient's Global Impression of Change (PGIC) | range 7 to 42, 7 indicating highest improvement | 3, 6, 12 & 24 months after treatment |
| SIH/ PDPH - Follow up - Self-administered comorbidity questionnaire (SCQ) | range 0 to 39, 0 indicating lowest burden | 12 & 24 months after treatment |
| SIH/PDPH - follow-up - current working capacity | range 0 to 5, 0 indicating full capacity | at 4 weeks & 3, 6, 12 & 24 months |
| SIH/PDPH - follow-up - complaints |
| 4 week, 3, 6, 12 & 24 months |
| SIH/PDPH - follow-up - headache severity | range 0 to 10, 10 indicating most severe pain | 4 week, 3, 6, 12 & 24 months |
| SIH/PDPH - follow-up - Days within the last month | with headaches with pain medication intake in the last month | 4 weeks, 3, 6, 12, 24 months |
| SIH/PDPH - follow-up - maximum duration being continuously upright | hours | 4 weeks, 3, 6, 12 & 24 months |
| SIH/PDPH - follow-up - severeness of dizziness | - in 0 to 10, 10 being most severe | 4 weeks, 3, 6, 12 &24 months |
| SIH/PDPH - follow-up - Severeness of shoulder- and neck pain | in 0 to 10, 10 being most severe | 4 weeks, 3, 6, 12 & 24 months |
| SIH/PDPH - follow-up - severeness of nausea | in 0 to 10, 10 being most severe | 4 weeks, 3, 6, 12 & 24 months |
| SIH/PDPH - follow-up - severeness of hearing disturbances and tinnitus | in 0 to 10, 10 being most severe | 4 weeks, 3, 6, 12 & 24 months |
| SIH/PDPH - follow-up - severeness of cognitive deficits | in 0 to 10, 10 being most severe | 4 weeks, 3, 6, 12 & 24 months |
| SIH/PDPH - follow-up - severeness of visual disturbances | in 0 to 10, 10 being most severe | 4 weeks, 3, 6, 12 & 24 months |
| SIH/PDPH - follow-up - exhaustion | rated between 0 to 5, with 5 indicating highest burden | 4 weeks, 3, 6,12 &24 months |
| SIH/PDPH - follow-up - ability to focus and concentrate | rated between 0 to 5, with 5 indicating highest burden | 4 weeks, 3, 6, 12 & 24 months |
| SIH/PDPH - follow-up - phase-contrast MRI: CSF-velocity (if performed) | cm/s | up to 6 months after treatment |
| SIH/PDPH - follow-up - phase-contrast MRI Stroke-volume CSF (if performed) | ml | up to 6 months after treatment |
| SIH/PDPH - follow-up - phase-contrast MRI Spinal cord motion (if performed) | mm | up to 6 months after treatment |
| SIH/PDPH - follow-up - phase-contrast MRI Spinal cord velocity (if performed) | cm/s | up to 6 months after treatment |
| 36544987 | Background | Schievink WI, Maya M, Barnard Z, Tache RB, Prasad RS, Wadhwa VS, Moser FG, Nuno M. The reversible impairment of behavioral variant frontotemporal brain sagging syndrome: Challenges and opportunities. Alzheimers Dement (N Y). 2022 Dec 18;8(1):e12367. doi: 10.1002/trc2.12367. eCollection 2022. |
| 36200700 | Background | Schievink WI, Maya MM, Harris J, Galvan J, Tache RB, Nuno M. Infratentorial Superficial Siderosis and Spontaneous Intracranial Hypotension. Ann Neurol. 2023 Jan;93(1):64-75. doi: 10.1002/ana.26521. Epub 2022 Oct 22. |
| 36447175 | Background | Sprave T, Gkika E, Verma V, Grosu AL, Stoian R. Patient reported outcomes based on EQ-5D-5L questionnaires in head and neck cancer patients: a real-world study. BMC Cancer. 2022 Nov 29;22(1):1236. doi: 10.1186/s12885-022-10346-4. |
| 30658932 | Background | Cella D, Grunwald V, Escudier B, Hammers HJ, George S, Nathan P, Grimm MO, Rini BI, Doan J, Ivanescu C, Paty J, Mekan S, Motzer RJ. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol. 2019 Feb;20(2):297-310. doi: 10.1016/S1470-2045(18)30778-2. Epub 2019 Jan 15. |
| 33891312 | Background | Niraj G, Mushambi M, Gauthama P, Patil A, Kelkar A, Hart E, Nurmikko T; Accidental Dural Puncture Outcome Study Collaborative Group. Persistent headache and low back pain after accidental dural puncture in the obstetric population: a prospective, observational, multicentre cohort study. Anaesthesia. 2021 Aug;76(8):1068-1076. doi: 10.1111/anae.15491. Epub 2021 Apr 23. |
| 25483233 | Background | Ranganathan P, Golfeiz C, Phelps AL, Singh S, Shnol H, Paul N, Attaallah AF, Vallejo MC. Chronic headache and backache are long-term sequelae of unintentional dural puncture in the obstetric population. J Clin Anesth. 2015 May;27(3):201-6. doi: 10.1016/j.jclinane.2014.07.008. Epub 2014 Dec 4. |
| 8490410 | Background | MacArthur C, Lewis M, Knox EG. Accidental dural puncture in obstetric patients and long term symptoms. BMJ. 1993 Apr 3;306(6882):883-5. doi: 10.1136/bmj.306.6882.883. |
| 36028627 | Background | Piechowiak EI, Aeschimann B, Hani L, Kaesmacher J, Mordasini P, Jesse CM, Schankin CJ, Raabe A, Schar RT, Gralla J, Beck J, Dobrocky T. Epidural Blood Patching in Spontaneous Intracranial Hypotension-Do we Really Seal the Leak? Clin Neuroradiol. 2023 Mar;33(1):211-218. doi: 10.1007/s00062-022-01205-7. Epub 2022 Aug 26. |
| 36087332 | Background | Beck J, Hubbe U, Klingler JH, Roelz R, Kraus LM, Volz F, Lutzen N, Urbach H, Kieselbach K, Fung C. Minimally invasive surgery for spinal cerebrospinal fluid leaks in spontaneous intracranial hypotension. J Neurosurg Spine. 2022 Sep 9;38(1):147-152. doi: 10.3171/2022.7.SPINE2252. Print 2023 Jan 1. |
| 34949452 | Background | Carlton Jones L, Butteriss D, Scoffings D. Spontaneous intracranial hypotension: the role of radiology in diagnosis and management. Clin Radiol. 2022 Mar;77(3):e181-e194. doi: 10.1016/j.crad.2021.11.007. Epub 2021 Dec 20. |
| 30776059 | Background | Dobrocky T, Grunder L, Breiding PS, Branca M, Limacher A, Mosimann PJ, Mordasini P, Zibold F, Haeni L, Jesse CM, Fung C, Raabe A, Ulrich CT, Gralla J, Beck J, Piechowiak EI. Assessing Spinal Cerebrospinal Fluid Leaks in Spontaneous Intracranial Hypotension With a Scoring System Based on Brain Magnetic Resonance Imaging Findings. JAMA Neurol. 2019 May 1;76(5):580-587. doi: 10.1001/jamaneurol.2018.4921. |
| 36945844 | Background | Pradeep A, Madhavan AA, Brinjikji W, Cutsforth-Gregory JK. Incidence of spontaneous intracranial hypotension in Olmsted County, Minnesota: 2019-2021. Interv Neuroradiol. 2025 Jun;31(3):364-368. doi: 10.1177/15910199231165429. Epub 2023 Mar 22. |
| 30923083 | Background | Farb RI, Nicholson PJ, Peng PW, Massicotte EM, Lay C, Krings T, terBrugge KG. Spontaneous Intracranial Hypotension: A Systematic Imaging Approach for CSF Leak Localization and Management Based on MRI and Digital Subtraction Myelography. AJNR Am J Neuroradiol. 2019 Apr;40(4):745-753. doi: 10.3174/ajnr.A6016. Epub 2019 Mar 28. |
| 37747369 | Background | Hani L, Fung C, El Rahal A, Volz F, Kraus LM, Schnell O, Ferrarese R, Erny D, Schwabenland M, Urbach H, Lutzen N, Beck J. Distinct Pattern of Membrane Formation With Spinal Cerebrospinal Fluid Leaks in Spontaneous Intracranial Hypotension. Oper Neurosurg. 2024 Jan 1;26(1):71-77. doi: 10.1227/ons.0000000000000914. Epub 2023 Sep 25. |
| 37582578 | Background | Uppal V, Russell R, Sondekoppam RV, Ansari J, Baber Z, Chen Y, DelPizzo K, Dirzu DS, Kalagara H, Kissoon NR, Kranz PG, Leffert L, Lim G, Lobo C, Lucas DN, Moka E, Rodriguez SE, Sehmbi H, Vallejo MC, Volk T, Narouze S. Evidence-based clinical practice guidelines on postdural puncture headache: a consensus report from a multisociety international working group. Reg Anesth Pain Med. 2024 Jul 8;49(7):471-501. doi: 10.1136/rapm-2023-104817. |
| 35701531 | Background | Jesse CM, Hani L, Fung C, Ulrich CT, Schar RT, Dobrocky T, Piechowiak EI, Goldberg J, Schankin C, Sintonen H, Beck J, Raabe A. The impact of spontaneous intracranial hypotension on social life and health-related quality of life. J Neurol. 2022 Oct;269(10):5466-5473. doi: 10.1007/s00415-022-11207-7. Epub 2022 Jun 14. |
| 27566748 | Background | Beck J, Ulrich CT, Fung C, Fichtner J, Seidel K, Fiechter M, Hsieh K, Murek M, Bervini D, Meier N, Mono ML, Mordasini P, Hewer E, Z'Graggen WJ, Gralla J, Raabe A. Diskogenic microspurs as a major cause of intractable spontaneous intracranial hypotension. Neurology. 2016 Sep 20;87(12):1220-6. doi: 10.1212/WNL.0000000000003122. Epub 2016 Aug 26. |
| 34822742 | Background | Kilic K, Korsbaek JJ, Jensen RH, Cvetkovic VV. Diagnosis of idiopathic intracranial hypertension - the importance of excluding secondary causes: A systematic review. Cephalalgia. 2022 May;42(6):524-541. doi: 10.1177/03331024211056580. Epub 2021 Nov 25. |
| 25987284 | Background | Ducros A, Biousse V. Headache arising from idiopathic changes in CSF pressure. Lancet Neurol. 2015 Jun;14(6):655-68. doi: 10.1016/S1474-4422(15)00015-0. |
| 36110926 | Background | Cheema S, Anderson J, Duncan C, Davagnanam I, Armstrong P, Redfern N, Ordman A, D'Antona L, Nissen J, Sayal P, Vaughan-Huxley E, Lagrata S, Iodice V, Snape-Burns J, Joy C, Matharu M. Survey of healthcare professionals' knowledge, attitudes and practices regarding spontaneous intracranial hypotension. BMJ Neurol Open. 2022 Sep 5;4(2):e000347. doi: 10.1136/bmjno-2022-000347. eCollection 2022. |
| 35058269 | Background | Cheema S, Joy C, Pople J, Snape-Burns J, Trevarthen T, Matharu M. Patient experience of diagnosis and management of spontaneous intracranial hypotension: a cross-sectional online survey. BMJ Open. 2022 Jan 20;12(1):e057438. doi: 10.1136/bmjopen-2021-057438. |
| 34274993 | Background | Hani L, Fung C, Jesse CM, Ulrich CT, Piechowiak EI, Gralla J, Raabe A, Dobrocky T, Beck J. Outcome after surgical treatment of cerebrospinal fluid leaks in spontaneous intracranial hypotension-a matter of time. J Neurol. 2022 Mar;269(3):1439-1446. doi: 10.1007/s00415-021-10710-7. Epub 2021 Jul 18. |
| 37652456 | Background | Volz F, Fung C, Wolf K, Lutzen N, Urbach H, Kraus LM, Omer M, Beck J, El Rahal A. Recovery and long-term outcome after neurosurgical closure of spinal CSF leaks in patients with spontaneous intracranial hypotension. Cephalalgia. 2023 Aug;43(8):3331024231196808. doi: 10.1177/03331024231195830. |
| Homepage. CSF Leak Association. Accessed September 5, 2023 | View source |
| SPINAL CSF LEAK CANADA. SPINAL CSF LEAK CANADA. Accessed September 5, 2023 | View source |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D014947 | Wounds and Injuries |
| D051271 | Headache Disorders, Secondary |
| D020773 | Headache Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |